Overview
- Amgen set a monthly cash price of $239 for Repatha, nearly 60% below the U.S. list price and matching its lowest price in any developed market.
- Purchases through AmgenNow do not use insurance, so buyers are not subject to prior authorization or step-therapy requirements.
- The program is open to eligible U.S. patients, including those who are uninsured or prefer to pay out of pocket.
- Amgen says the portal will be accessible through the Trump administration’s planned TrumpRx website, following the president’s push for price parity and direct-to-consumer options.
- The launch follows Amgen’s report that the VESALIUS‑CV trial found Repatha reduced major cardiovascular events in people without prior heart attack or stroke.